Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer

Fig. 2

Ex vivo biodistribution measured at 24 and 48 h after administration of a a microdose of 64Cu-MN-anti-miR10b (%ID/g), b a therapeutic carrier-added macrodose of 64Cu-MN-anti-miR10b (%ID/g). Insets show the %ID/g values in liver and spleen. #Denotes organs with metastasis as detected by BLI. Error bars represent standard error of the mean. Correlation between the %ID/g in non-metastatic organs obtained after administration of a microdose and the %ID/g obtained after administration of a macrodose at c 24 h and d 48 h post-injection (c and d Pearson product–moment correlation, the dashed line corresponds to the line of identity)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us